These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 8280800)

  • 1. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
    Liem SE; Ramezani A; Li X; Joshi S
    Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics.
    Ragheb JA; Bressler P; Daucher M; Chiang L; Chuah MK; VandenDriessche T; Morgan RA
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1343-53. PubMed ID: 8573391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator.
    Bevec D; Dobrovnik M; Hauber J; Böhnlein E
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9870-4. PubMed ID: 1409715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.
    Bauer G; Valdez P; Kearns K; Bahner I; Wen SF; Zaia JA; Kohn DB
    Blood; 1997 Apr; 89(7):2259-67. PubMed ID: 9116267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
    Ding SF; Lombardi R; Nazari R; Joshi S
    Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
    Mautino MR; Morgan RA
    Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
    Ragheb JA; Couture L; Mullen C; Ridgway A; Morgan RA
    Hum Gene Ther; 1999 Jan; 10(1):103-12. PubMed ID: 10022535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule.
    Lisziewicz J; Zeng G; Gratas C; Weinstein JN; Lori F
    Hum Gene Ther; 2000 Apr; 11(6):807-15. PubMed ID: 10779158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-1 by a double transdominant fusion gene.
    Aguilar-Cordova E; Chinen J; Donehower LA; Harper JW; Rice AP; Butel JS; Belmont JW
    Gene Ther; 1995 May; 2(3):181-6. PubMed ID: 7614248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
    Bai J; Banda N; Lee NS; Rossi J; Akkina R
    Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins.
    Ulich C; Harrich D; Estes P; Gaynor RB
    J Virol; 1996 Jul; 70(7):4871-6. PubMed ID: 8676525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tat and rev differentially affect restricted replication of human immunodeficiency virus type 1 in various cells.
    Duan L; Oakes JW; Ferraro A; Bagasra O; Pomerantz RJ
    Virology; 1994 Mar; 199(2):474-8. PubMed ID: 8122376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for CTL-mediated selection of Tat and Rev mutants after the onset of the asymptomatic period during HIV type 1 infection.
    Guillon C; Stankovic K; Ataman-Onal Y; Biron F; Verrier B
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1283-92. PubMed ID: 17209772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
    Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
    Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helper plasmids for production of HIV-1-derived vectors.
    Fuller M; Anson DS
    Hum Gene Ther; 2001 Nov; 12(17):2081-93. PubMed ID: 11747598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tat gene and protein of the human immunodeficiency virus type 1.
    Caputo A; Grossi MP; Rossi C; Campioni D; Balboni PG; Corallini A; Barbanti-Brodano G
    New Microbiol; 1995 Jan; 18(1):87-110. PubMed ID: 7760763
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
    Mautino MR; Keiser N; Morgan RA
    J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector.
    Venkatesh LK; Arens MQ; Subramanian T; Chinnadurai G
    Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8746-50. PubMed ID: 2247444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of HIV-1 envelope protein synthesis by Tat and Rev in 293 cells.
    Natarajan V; Radjendirane V; Salzman NP
    Virology; 1993 Sep; 196(1):122-9. PubMed ID: 8356789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.